相关实验视频

Updated: May 5, 2026

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model

Published on: September 4, 2017

除了强大的异常值外,拉巴胺在脑洞形形的小鼠模型中增加了损伤负担

Roberto J Alcazar-Felix¹, Robert Shenkar¹, Christian R Benavides²

¹Department of Neurological Surgery, Pritzker School of Medicine and Biological Sciences Division, University of Chicago, Chicago, IL, 60637, USA.

Translational stroke research

|July 9, 2024

概括

拉巴胺可能会在缺乏PIK3CA突变的小鼠中阻止大脑洞腔形 (CCM),但可能会加剧整体病变负担并增加磨损. 对于家族性CCM疾病的治疗,需要进一步的研究.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一个
药理学药理学是指药理学的学科.

背景情况:

大脑洞腔形 (CCM) 是一种与CCM基因内皮突变相关的出血性脑血管疾病.
在许多CCM病例中存在体质PIK3CA功能增益 (GOF) 突变.
拉巴胺素 (一种mTORC1抑制剂) 已在抑制由CCM基因损失和Pik3ca GOF.驱动的小鼠CCM病变进展方面表现有前途.

研究的目的:

在没有PIK3CA GOF诱导的家族CCM疾病的小鼠模型中研究拉巴素对病变发展的影响.
为了比较安慰剂和拉帕素治疗小鼠之间的损伤负担,磨损和出血.
通过血miRNome分析来识别拉巴胺素反应的潜在生物标志物.

主要方法:

使用Ccm3-/-PDGFb-icreERPositive对家族性CCM疾病的小鼠模型.
在三个临床上相关的剂量或安慰剂中服用拉巴胺素.
评估了损伤负担,磨损和出血;分析了血miRNome.

主要成果:

异常大的异常值CCM病变仅在安慰剂组中观察到.
拉巴胺似乎在所有剂量中防止了这些大型异常病变的出现.
然而,拉巴胺似乎也加剧了平均病变负担 (不包括异常值),增加了磨损,并没有影响出血.
在接受拉帕素治疗的小鼠中,miR-30c-2-3p降低,并准PI3K/AKT和mTOR信号通路.

结论:

在非由PIK3CA GOF驱动的家族CCM模型中,拉巴胺可能会阻止异常病变的进展.
这种潜在的好处可能以增加平均损伤负担和磨损的成本来实现.
需要进行进一步的研究,以阐明调解拉巴胺素作用的特定途径,以及体质PIK3CA突变是否影响病变的攻击性.

关键词:

在CCM中,我们可以使用CCM.大脑洞穴性形鼠标鼠标是一个鼠标.这是一种ROCK抑制剂.拉帕米辛是一种可怕的药物.一次性中风,中风.

更多相关视频

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...